Pioneer and undisputed leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type able to grow new muscle.
Bioheart, Inc. is the first co. to address the underlying cause of heart failure in more than 50 million patients worldwide, which is untreated scar tissue following a heart attack. We began our clinical trials in 2001 and stand 7 years ahead of the nearest competitor in bringing a cell composition able to grow new muscle in heart scar tissue to market. Our Phase II/III MARVEL randomized placebo controlled study demonstrated 500% improvement.